目的 觀察血必凈注射液聯(lián)合人免疫球蛋白治療重癥病毒性肺炎的臨床療效。方法 選取2012年1月-2015年12月在南京市第一醫(yī)院住院治療的重癥病毒性肺炎患者92例，隨機分為對照組和治療組，每組各46例。對照組患者靜脈注射靜注人免疫球蛋白（pH 4），10 g/次，1次/d；治療組在對照組的基礎上靜脈注射血必凈注射液，50 mL/次，2次/d。兩組患者均連續(xù)治療7 d。治療后，比較兩組患者臨床療效、臨床癥狀體征改善及高敏C反應蛋白（hs-CRP）、白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）的水平改變。結果 治療后，對照組和治療組的總有效率分別為82.61%和91.30%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組患者退熱時間、咳嗽和氣喘消退時間明顯短于對照組，兩組臨床癥狀體征改善情況比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者hs-CRP、IL-6、TNF-α水平均明顯降低，同組治療前后比較具有統(tǒng)計學意義（P<0.05）；且治療組上述炎癥因子降低程度更明顯，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 血必凈注射液聯(lián)合人免疫球蛋白治療重癥病毒性肺炎臨床療效顯著，能有效改善患者的癥狀體征和炎癥因子，具有一定的臨床推廣應用價值。

Objective To observe the clinical curative effect of Xuebijing Injection combined with human immunoglobulin in treatment of severe viral pneumonia. Methods Patients (92 cases) with severe viral pneumonia in Nanjing First Hospital from January 2012 to December 2015 were randomly divided into control and treatment groups, and each group had 46 cases. The patients in the control group were iv administered with Human Immunoglobulin (pH 4) for iv injection, 10 g/time, once daily. The patients in the treatment group were iv administered with Xuebijing Injection on the basis of the control group, 50 mL/time, twice daily. The patients in two groups were treated for 7 d. After treatment, the efficacy and the clinical symptoms and signs were evaluated, and hs-CRP, IL-6, and TNF-α in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 82.61% and 91.30%, respectively, and there were differences between two groups (P<0.05). After treatment, antifebrile time, cough and asthma disappeared time in the treatment group were significantly shorter than those in the control group, with significant differences between two groups (P<0.05). And after treatment, the levels of hs-CRP, IL-6, and TNF-α in two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And the decrease degree of those inflammatory factors in the treatment group was more significant than that in the control group, with significant differences between two groups (P<0.05). Conclusion Xuebijing Injection combined with human immunoglobulin has a significant clinical curative effect in treatment of severe viral pneumonia, can effectively improve the symptoms and signs and inflammatory factors, which has a certain clinical application value.